Paul Hastings Advised Piper Sandler on $42 Million Private Placement in Connection with Q32 Bio and Homology Medicines Merger
Paul Hastings LLP advised Piper Sandler on a $42 million private placement in connection with the merger of Q32 Bio and Homology Medicines (Nasdaq: FIXX). Leerink Partners LLC also acted as a placement agent in the private placement. The concurrent private placement supports clinical development through multiple milestones, including Phase 2 readouts for bempikart, initial ADX-097 proof-of-concept data by year-end 2024, and ADX-097 results in 2025. The combined company subject to completion of the merger, Q32 Bio (Nasdaq: QTTB), is a clinical stage biotechnology company developing biologic therapeutics targeting potent regulators of the innate and adaptive immune systems to re-balance immunity in autoimmune and inflammatory diseases.
Partner and co-head of Equity Capital Markets and co-chair of the Corporate Life Sciences Group Seo Salimi and Securities and Capital Markets partner Will Magioncalda led the Paul Hastings team.
More information about the transaction can be found here.
With widely recognized elite teams across 18 core practices, Paul Hastings is a premier law firm with a culture of excellence focused on providing intellectual capital and superior execution globally to the world's leading investment banks, asset managers and corporations.